Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-or...

Descripción completa

Detalles Bibliográficos
Autores: Katagiri, Yuki, Onuma, Yoshinobu, Asano, Taku, Iñiguez Romo, Andres, Jensen, Lisette Okkels, Cequier Fillat, Àngel R., Hofma, Sjoerd H., Christiansen, Evald H., Suttorp, Maarten, Brugaletta, Salvatore, Räber, Lorenz, Sabaté Tenas, Manuel, Windecker, Stephan, Serruys, Patrick W.
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/172268
Acceso en línea:https://hdl.handle.net/2445/172268
Access Level:acceso embargado
Palabra clave:Malalties coronàries
Infart de miocardi
Coronary diseases
Myocardial infarction
Descripción
Sumario:Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.

Similares en LA Referencia